Robert B Belshe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7631695/publications.pdf

Version: 2024-02-01

471509 477307 1,739 29 17 29 citations h-index g-index papers 30 30 30 2558 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response. Journal of Immunology, 2010, 184, 2518-2527.	0.8	472
2	The need for quadrivalent vaccine against seasonal influenza. Vaccine, 2010, 28, D45-D53.	3.8	168
3	Prevaccine Determination of the Expression of Costimulatory B7 Molecules in Activated Monocytes Predicts Influenza Vaccine Responses in Young and Older Adults. Journal of Infectious Diseases, 2007, 195, 1590-1597.	4.0	152
4	Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses. Science Immunology, 2017, 2, .	11.9	122
5	Safety, Efficacy, and Effectiveness of Live, Attenuated, Coldâ€Adapted Influenza Vaccine in an Indicated Population Aged 5–49 Years. Clinical Infectious Diseases, 2004, 39, 920-927.	5.8	98
6	Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women. Journal of Infectious Diseases, 2014, 209, 828-836.	4.0	94
7	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naÃ-ve subjects. Vaccine, 2015, 33, 5225-5234.	3.8	92
8	Aging-dependent alterations in gene expression and a mitochondrial signature of responsiveness to human influenza vaccination. Aging, 2015, 7, 38-52.	3.1	72
9	Prolonged Proinflammatory Cytokine Production in Monocytes Modulated by Interleukin 10 After Influenza Vaccination in Older Adults. Journal of Infectious Diseases, 2015, 211, 1174-1184.	4.0	62
10	Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization. Journal of Virology, 2014, 88, 14278-14288.	3.4	60
11	Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant. Journal of Infectious Diseases, 2011, 203, 666-673.	4.0	56
12	Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1420.	7.4	45
13	Evaluation of smallpox vaccines using variola neutralization. Journal of General Virology, 2009, 90, 1962-1966.	2.9	44
14	Doseâ€Dependent Neutralizingâ€Antibody Responses to Vaccinia. Journal of Infectious Diseases, 2004, 189, 493-497.	4.0	33
15	Repertoire of Epitopes Recognized by Serum IgG from Humans Vaccinated with Herpes Simplex Virus 2 Glycoprotein D. Journal of Virology, 2014, 88, 7786-7795.	3.4	31
16	Seasonal Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and Older Adults. Journal of Immunology, 2020, 204, 1661-1673.	0.8	28
17	HIV Type 1 Vaccine-Induced T Cell Memory and Cytotoxic T Lymphocyte Responses in HIV Type 1-Uninfected Volunteers. AIDS Research and Human Retroviruses, 2001, 17, 1175-1189.	1.1	24
18	Molecular Evolution of Herpes Simplex Virus 2 Complete Genomes: Comparison between Primary and Recurrent Infections. Journal of Virology, 2017, 91, .	3.4	22

#	Article	IF	CITATIONS
19	Influenza Prevention and Treatment: Current Practices and New Horizons. Annals of Internal Medicine, 1999, 131, 621.	3.9	10
20	Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines. Journal of Infectious Diseases, 2022, 226, 1489-1498.	4.0	10
21	Development of a high-throughput \hat{l}^2 -Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples. Vaccine, 2016, 34, 3901-3906.	3.8	7
22	Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses. PLoS ONE, 2015, 10, e0144738.	2.5	7
23	Neutralizing Antibody Kinetics and Immune Protection Against Herpes Simplex Virus 1 Genital Disease in Vaccinated Women. Journal of Infectious Diseases, 2023, 227, 522-527.	4.0	7
24	The Potential of Live, Attenuated Influenza Vaccine for the Prevention of Influenza in Children. Clinical Infectious Diseases, 2019, 69, 795-796.	5.8	5
25	The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects. PLoS ONE, 2017, 12, e0176687.	2.5	5
26	Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine, 2016, 34, 547-554.	3.8	4
27	Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays. PLoS ONE, 2019, 14, e0214467.	2.5	4
28	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009–2010 seasonal trivalent influenza vaccinations. Vaccine, 2015, 33, 163-173.	3.8	3
29	Molecular analyses and phylogeny of the herpes simplex virus 2 US9 and glycoproteins gE/gl obtained from infected subjects during the Herpevac Trial for Women. PLoS ONE, 2019, 14, e0212877.	2.5	2